secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001299130-25-000011
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio reports preliminary Q4 revenue $39.2M, down 33% YoY; Vega system shipped ahead of schedule
--------------------------------------------------------------------------------

- Preliminary Q4 revenue $39.2M vs $58.4M prior year (-33%); full year $154M vs $200M (-23%).
- Instrument revenue $15.3M (23 Revio, 7 Vega systems); consumables revenue $18.8M flat YoY.
- Launched Vega benchtop system ahead of schedule and SPRQ chemistry enabling sub-$500 HiFi genome.
- Strengthened balance sheet: exchanged $459M of 2028 notes for $200M notes due 2029, 20.5M shares, and $50M cash.
- Preliminary cash and investments $390M as of Dec 31, 2024; final results subject to audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000011/0001299130-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913025000011/pacb-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001299130-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer